benserazide has been researched along with Diarrhea in 3 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma elimination half life, thereby prolonging the efficacy of levodopa." | 2.69 | Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. ( Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hedge, SS | 1 |
| Moy, TM | 1 |
| Perry, MR | 1 |
| Loeb, M | 1 |
| Eglen, RM | 1 |
| Bourin, M | 1 |
| Hascoet, M | 1 |
| Deguiral, P | 1 |
| Baas, H | 1 |
| Beiske, AG | 1 |
| Ghika, J | 1 |
| Jackson, M | 1 |
| Oertel, WH | 1 |
| Poewe, W | 1 |
| Ransmayr, G | 1 |
1 trial available for benserazide and Diarrhea
| Article | Year |
|---|---|
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dia | 1998 |
2 other studies available for benserazide and Diarrhea
| Article | Year |
|---|---|
Evidence for the involvement of 5-hydroxytryptamine 4 receptors in 5-hydroxytryptophan-induced diarrhea in mice.
Topics: 5-Hydroxytryptophan; Animals; Atropine; Benserazide; Benzimidazoles; Bridged Bicyclo Compounds; Brid | 1994 |
5-HTP induced diarrhea as a carcinoid syndrome model in mice?
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Carcinoid Tumor; Defecation; Diarrhea; Disease Models, An | 1996 |